Selection of Osteoporosis Medications

For adults with osteoporosis, oral bisphosphonates (alendronate or risedronate) are the first-line treatment for most patients at moderate-to-high fracture risk, while anabolic agents (romosozumab, teriparatide, or abaloparatide) should be initiated first in patients at very high fracture risk, followed by sequential antiresorptive therapy.

Risk Stratification Determines Initial Therapy

The choice of osteoporosis medication fundamentally depends on fracture risk stratification, which directly impacts morbidity and mortality outcomes:

Very High Risk Patients

Patients at very high risk include those with:

Recent fragility fracture (especially spine or hip)
Multiple vertebral fractures
Fractures while on osteoporosis therapy
Very low T-scores (≤-3.0)
High fall risk or frailty
Very high FRAX scores (≥20% major osteoporotic fracture or ≥3% hip fracture)
High-dose glucocorticoid use

For these patients, initiate with anabolic agents first 1. The 2020 AACE guidelines explicitly recommend abaloparatide, romosozumab, teriparatide, or zoledronate as first-line options for very high-risk patients, with denosumab as an alternative 1. This anabolic-first approach produces superior bone mineral density gains and greater fracture risk reduction compared to starting with antiresorptives 2, 3.

High-to-Moderate Risk Patients

For adults ≥40 years at high risk (but not very high risk), oral bisphosphonates remain the strongly recommended first-line therapy 4, 5. The preference hierarchy when oral bisphosphonates are inappropriate is:

IV bisphosphonates (zoledronate)
Teriparatide
Denosumab
Raloxifene (postmenopausal women only, when other options unsuitable)

This hierarchy is based on safety profile, cost, and equivalent antifracture efficacy 4, 5.

Specific Medication Indications

Oral Bisphosphonates (Alendronate, Risedronate)

First-line for high/moderate risk patients ≥40 years 4, 5
Preferred due to proven fracture reduction, favorable safety profile, and low cost
Strong recommendation for high-risk patients; conditional for moderate-risk 4
Also first-line for adults <40 years with moderate-to-high fracture risk 4

Denosumab

Alternative when bisphosphonates inappropriate 4, 1
First-line option for very high-risk patients 1
Critical caveat: Requires structured transition to bisphosphonates upon discontinuation to prevent rebound bone loss and multiple vertebral fractures 6, 7, 8. This is a serious safety concern that affects quality of life and mortality.
Concerns exist about safety in patients on immunosuppressive agents 4

Teriparatide

First-line for very high-risk patients 1
Third-line when bisphosphonates and IV bisphosphonates inappropriate in high-risk patients 4
Limit treatment to 2 years maximum 6
Must be followed by antiresorptive therapy (bisphosphonate or denosumab) to maintain gains 6, 8
Cost and daily injection burden are considerations 4

Abaloparatide

First-line for very high-risk patients 1
Similar profile to teriparatide
Limit to 2 years, must follow with antiresorptive 6

Romosozumab

First-line for very high-risk patients 1
Particularly effective: dual mechanism (increases bone formation, decreases resorption)
Limit to 1 year, must follow with bisphosphonate or denosumab 6
Sequential romosozumab→denosumab or romosozumab→bisphosphonates produces robust BMD gains 2, 9
Important contraindication: Cardiovascular concerns limit use in patients with MI or stroke history 9

Sequential Therapy: Critical for Optimal Outcomes

Sequential therapy is not optional—it is essential for maintaining treatment gains and preventing fracture, directly impacting morbidity and mortality:

After Anabolic Therapy

All anabolic agents MUST be followed by antiresorptive therapy 6, 8, 2:

After romosozumab (1 year): transition to denosumab or bisphosphonate 6, 9
After teriparatide/abaloparatide (2 years): transition to bisphosphonate or denosumab 6, 8
Failure to transition results in rapid bone loss and loss of fracture protection 8

After Bisphosphonates

Consider drug holiday after 5 years oral or 3-6 years IV bisphosphonates only if fracture risk no longer high 6, 1
If still high risk: continue bisphosphonates or switch to anabolic agent 1
Switching from bisphosphonates to romosozumab yields robust hip BMD gains 2
Switching from bisphosphonates to teriparatide shows attenuated hip response 2, 10

After Denosumab

Never simply discontinue denosumab—this causes rebound bone loss and multiple vertebral fractures 6, 7, 8. Must transition to bisphosphonate therapy 6, 7.

Evidence Quality and Nuances

The strongest evidence comes from the 2020 AACE guidelines 1 and 2022 ACR glucocorticoid-induced osteoporosis guidelines 11, which incorporate the most recent data on anabolic agents. The 2017 ACR guidelines 4, 5 provide robust evidence for bisphosphonate use but predate romosozumab approval.

Key divergence: The 2020 AACE guidelines 1 more strongly advocate anabolic-first strategies for very high-risk patients compared to earlier guidelines, reflecting accumulating evidence that anabolic-first sequential therapy produces superior outcomes 2, 3.

Common Pitfalls to Avoid

Starting antiresorptives in very high-risk patients: This delays optimal bone formation and may attenuate subsequent anabolic response 2, 10, 3
Discontinuing anabolic agents without antiresorptive follow-up: Results in rapid bone loss 8
Stopping denosumab without transition therapy: Causes rebound vertebral fractures—a serious, preventable complication 6, 7, 8
Inappropriate drug holidays: Only consider after 5+ years oral or 3-6 years IV bisphosphonates, and only when fracture risk is no longer high 6, 1
Using romosozumab in patients with recent MI/stroke: Cardiovascular safety concerns contraindicate use 9
Ignoring cost and adherence: Daily injections (teriparatide, abaloparatide) have higher burden than monthly injections (romosozumab) or oral/annual IV options 4

What are the recommended first‑line and subsequent medication options for adults with osteoporosis, including indications for oral bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab?

Have a follow-up question?